



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 6 Oct 2021 (#32)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notices of Special Interest

**[NOT-HL-22-002](#) Notice of Special Interest: Resilience and Vulnerability following Acute Heart, Lung, Blood, and Sleep Insults in People with HIV (R01, Clinical Trial Not Allowed).** This NOSI encourages the submission of research project applications focused on understanding the long-term manifestations of acute chronic heart, lung, blood, and sleep-related (HLBS) illnesses with an emphasis on host response, viral pathways, and mechanisms that contribute to long-term manifestations in the context of HIV. Proposals considered responsive to the NOSI may address questions across the spectrum of basic science to population science. First Available Due Date: January 07, 2022. Submit applications for this initiative using the following Funding Opportunity Announcements (FOA) or **any reissue of this announcement**:

[PA-20-185](#)- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

**[NOT-NS-22-010](#) Notice of Special Interest: Biomarker Discover and Validation in Functional Neurological Disorders.** NINDS is issuing this Notice of Special Interest to encourage the submission of applications focused on the development and validation of biomarkers for functional neurological disorders (FND). FND are a complex and heterogeneous group of neuropsychiatric syndromes. They are characterized by symptoms of altered voluntary motor or sensory function and frequently have comorbid medical, neurological, and psychiatric disorders. This notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through January 8, 2025. Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissue of this announcement:

[PAR-19-315](#) - Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)

[PAR-21-056](#) - Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)

[PAR-21-058](#) - Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)

## Funding Opportunity Announcements (FOA)

### 1. Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-21-344](#)

**Type:** R01

**Application Due Date:** December 20, 2021; December 20, 2022. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The purpose of this FOA is to solicit Research Project Grant (R01) applications for up to 3 years of support to develop and test interventions to reduce the impact of HIV-associated stigma on the prevention and treatment of HIV infection and/or AIDS, and on the quality of life of People Living with HIV and/or AIDS (PLWH). The FOA will also support interventions to address the multiple intersecting stigmas and measurement of the stigmas at individual levels. Specifically, this initiative will support intervention research on a) novel stigma reduction strategies that link to increase in care-seeking behavior and/or decrease in transmission, b) reducing the impact of stigma on adolescent and/or youth health, c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/co-infections, d) reducing the effects of stigma on, and/or by, family members or care givers of PLWH and e) development of innovative and improved stigma measurement in the context of implementation of a stigma-reduction intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to conduct exploratory studies to determine the feasibility of stigma-reduction interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).

**Budget:** The combined budget for direct costs for the three-year project period may not exceed \$400,000. No more than \$200,000 in direct costs may be requested in any single year. The budget request must reflect the actual needs of the proposed project. Applicants may request a project period of up to three years.

### 2. The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-21-348](#)

**Type:** U01

**Application Due Date:** December 15, 2021; December 15, 2022; December 15, 2023. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) focuses on the role of EBV infection on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection. The goal is to increase our knowledge through mechanistic, epidemiological, or translational studies that examine how EBV promotes NHL or HD initiation, progression, and the resulting disease sequelae and to provide insights into mechanistic differences in the relationship between EBV infection and lymphomagenesis in HIV+ versus HIV- persons. Research project U01s funded through this PAR will form a cooperative group, the Epstein Barr Virus associated Lymphoma Consortium (EALC).

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

### 3. Role of Astrocytes in Degeneration of the Neurovascular Unit in AD/ADRDs (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-037](#)

**Type:** R01

**Application Due Date:** February 04, 2022. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) invites basic disease-related research to address a gap in the basic research on the mechanisms of reactive astrogliosis in degeneration of the neurovascular unit that contributes to cognitive impairment and dementia. The neurovascular unit involves multiple pathways that contribute to neurodegeneration. Astrocytes, due to their overlapping roles regulating the blood brain barrier, neuronal health and response to degenerating cells, are uniquely positioned to be therapeutic targets for the AD/ADRDs.

**Budget:** NINDS intends to commit \$3.75M per year in FY2022 to fund five awards. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets need to reflect the actual needs of the proposed project. Budgets are limited to \$500,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is five years.

### 4. Systems Biology for Infectious Diseases (U19 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-21-065](#)

**Type:** U19

**Application Due Date:** January 14, 2022. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The purpose of the Funding Opportunity Announcement (FOA) is to support research that employs systems biology approaches to human pathogens. The approach will generate and integrate large datasets into models that guide in vitro, in vivo and clinical studies, with the goals of predicting disease severity, predicting responses to vaccines and therapeutics, and identifying candidate targets for interventions.

**Budget:** NIAID intends to commit \$10 million in FY 2023 to fund 4-5 awards. Budgets for direct costs of up to \$1,500,000 per year may be requested. Application budgets need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105